Genome-wide significant risk associations for mucinous ovarian carcinoma

Nature Genetics

Volumn 47, Issue 8, 2015, Pages 888-897

  Kelemen, Linda E ^a   Lawrenson, Kate ^b   Tyrer, Jonathan ^c   Li, Qiyuan ^d,e   Lee, Janet M ^b   Seo, Ji Heui ^e   Phelan, Catherine M ^f   Beesley, Jonathan ^g   Chen, Xiaoqing ^g   Spindler, Tassja J ^b   Aben, Katja K H ^h,i   Anton Culver, Hoda ^j   Antonenkova, Natalia ^k   Baker, Helen ^l   Bandera, Elisa V ^m   Bean, Yukie ^n,o   Beckmann, Matthias W ^p   Bisogna, Maria ^q   Bjorge, Line ^r,s   Bogdanova, Natalia ^t   Brinton, Louise A ^u   Brooks Wilson, Angela ^v,w   Bruinsma, Fiona ^x   Butzow, Ralf ^y   Campbell, Ian G ^z,aa,ab   Carty, Karen ^ac   Chang Claude, Jenny ^ad   Chen, Y Ann ^f   Chen, Zhihua ^f   Cook, Linda S ^ae   Cramer, Daniel W ^af,ag   Cunningham, Julie M ^ah   Cybulski, Cezary ^ai   Dansonka Mieszkowska, Agnieszka ^aj   Dennis, Joe ^l   Dicks, Ed ^l   Doherty, Jennifer A ^ak   Dörk, Thilo ^t   Bois, Andreas Du ^al,am   Dürst, Matthias ^an   Eccles, Diana ^ao   Easton, Douglas T ^l   Edwards, Robert P ^ap   Eilber, Ursula ^ad   Ekici, Arif B ^aq   Engelholm, Svend Aage ^ar   Fasching, Peter A ^p,as   Fridley, Brooke L ^at   Gao, Yu Tang ^au   Gentry Maharaj, Aleksandra ^av   Giles, Graham G ^x,ab,aw   Glasspool, Rosalind ^ac   Goode, Ellen L ^ah   Goodman, Marc T ^ax   Grownwald, Jacek ^ai   Harrington, Patricia ^c   Harter, Philipp ^al,am   Hasmad, Hanis Nazihah ^ay   Hein, Alexander ^p   Heitz, Florian ^al,am   Hildebrandt, Michelle A T ^az   Hillemanns, Peter ^t   Hogdall, Estrid ^ar,ba   Hogdall, Claus ^ar   Hosono, Satoyo ^bb   Iversen, Edwin S ^bc   Jakubowska, Anna ^ai   Jensen, Allan ^ba   Ji, Bu Tian ^u   Karlan, Beth Y ^ax   Kellar, Melissa ^n,o   Kelley, Joseph L ^ap   Kiemeney, Lambertus A ^h   Krakstad, Camilla ^r,s   Kjaer, Susanne K ^ar,ba   Kupryjanczyk, Jolanta ^aj   Lambrechts, Diether ^bd,be   Lambrechts, Sandrina ^bf   Le, Nhu D ^v   Lee, Alice W ^b   Lele, Shashi ^bg   Leminen, Arto ^y   Lester, Jenny ^ax   Levine, Douglas A ^q   Liang, Dong ^bh   Lissowska, Jolanta ^aj   Lu, Karen ^az   Lubinski, Jan ^ai   Lundvall, Lene ^ar   Massuger, Leon F A G ^h   Matsuo, Keitaro ^bi   McGuire, Valerie ^bj   McLaughlin, John R ^bk   McNeish, Iain ^bl   Menon, Usha ^av   Modugno, Francesmary ^ap,bm,bn   Moes Sosnowska, Joanna ^aj   Moysich, Kirsten B ^bg   Narod, Steven A ^bo   Nedergaard, Lotte ^ar   Ness, Roberta B ^bp   Nevanlinna, Heli ^y   Adenan, Noor Azmi Mat ^bq   Odunsi, Kunle ^bg   Olson, Sara H ^q   Orlow, Irene ^q   Orsulic, Sandra ^ax   Weber, Rachel Palmieri ^br   Paul, James ^ac   Pearce, Celeste Leigh ^b,bs   Pejovic, Tanja ^n,o   Pelttari, Liisa M ^y   Permuth Wey, Jennifer ^f   Pike, Malcolm C ^b,q   Poole, Elizabeth M ^af,bt   Ramus, Susan J ^b   Risch, Harvey A ^bu   Rosen, Barry ^bv   Rossing, Mary Anne ^bw,bx   Rothstein, Joseph H ^bj   Rudolph, Anja ^ad   Runnebaum, Ingo B ^an   Rzepecka, Iwona K ^aj   Salvesen, Helga B ^r,s   Schildkraut, Joellen M ^br,by   Schwaab, Ira ^bz   Shu, Xiao Ou ^ca   Shvetsov, Yurii B ^cb   Siddiqui, Nadeem ^cc   Sieh, Weiva ^bj   Song, Honglin ^c,l   Southey, Melissa C ^aa   Sucheston, Lara ^bg   Tangen, Ingvild L ^r,s   Teo, Soo Hwang ^ay,bq   Terry, Kathryn L ^af,ag   Thompson, Pamela J ^ax   Tworoger, Shelley S ^af,bt   Van Altena, Anne M ^h   Nieuwenhuysen, Els Van ^bf   Vergote, Ignace ^bf   Vierkant, Robert A ^ah   Shan, Wang Gohrke ^cd   Walsh, Christine ^ax   Wentzensen, Nicolas ^u   Whittemore, Alice S ^bj   Wicklund, Kristine G ^bw   Wilkens, Lynne R ^cb   Sawicki, Wlodzimierz ^ce   Woo, Yin Ling ^bq   Wu, Xifeng ^az   Wu, Anna H ^b   Yang, Hannah ^u   Zheng, Wei ^ca   Ziogas, Argyrios ^j   Sellers, Thomas A ^f   Freedman, Matthew L ^e   Chenevix Trench, Georgia ^g   Pharoah, Paul D P ^c,l   Gayther, Simon A ^b   Berchuck, Andrew ^cf   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d XIAMEN UNIVERSITY   (China)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Department of Cancer Registry and Research   (Netherlands)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Byelorussian Institute for Oncology and Medical Radiology Aleksandrov NN   (Belarus)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^s UNIVERSITY OF BERGEN   (Norway)

^t HANNOVER MEDICAL SCHOOL   (Germany)

^u NATIONAL CANCER INSTITUTE   (United States)

^v BRITISH COLUMBIA CANCER AGENCY   (Canada)

^w SIMON FRASER UNIVERSITY   (Canada)

^x CANCER EPIDEMIOLOGY CENTRE   (Australia)

^y UNIVERSITY OF HELSINKI   (Finland)

^z PETER MACCALLUM CANCER CENTRE   (Australia)

^aa UNIVERSITY OF MELBOURNE   (Australia)

^ab UNIVERSITY OF MELBOURNE   (Australia)

^ac BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^ad GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ae UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^af HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ag BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ah MAYO CLINIC   (United States)

^ai POMERANIAN MEDICAL UNIVERSITY   (Poland)

^aj INSTITUTE OF ONCOLOGY   (Poland)

^ak DARTMOUTH MEDICAL SCHOOL   (United States)

^al KLINIKEN ESSEN MITTE   (Germany)

^am DR HORST SCHMIDT KLINIKEN   (Germany)

^an JENA UNIVERSITY HOSPITAL   (Germany)

^ao UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^ap UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^aq UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ar UNIVERSITY OF COPENHAGEN   (Denmark)

^as UNIVERSITY OF CALIFORNIA   (United States)

^at UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^au SHANGHAI CANCER INSTITUTE   (China)

^av UNIVERSITY COLLEGE LONDON   (United Kingdom)

^aw MONASH UNIVERSITY   (Australia)

^ax CEDARS SINAI MEDICAL CENTER   (United States)

^ay CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^az UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ba DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^bb AICHI CANCER CENTER HOSPITAL   (Japan)

^bc Duke University   (United States)

^bd UNIVERSITY OF LEUVEN   (Belgium)

^be UNIVERSITY OF LEUVEN   (Belgium)

^bf UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^bg ROSWELL PARK CANCER INSTITUTE   (United States)

^bh TEXAS SOUTHERN UNIVERSITY   (United States)

^bi KYUSHU UNIVERSITY   (Japan)

^bj STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bk PUBLIC HEALTH ONTARIO   (Canada)

^bl UNIVERSITY OF GLASGOW   (United Kingdom)

^bm UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^bn UNIVERSITY OF PITTSBURGH   (United States)

^bo UNIVERSITY OF TORONTO   (Canada)

^bp UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^bq UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^br DUKE UNIVERSITY MEDICAL CENTER   (United States)

^bs UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^bt HARVARD MEDICAL SCHOOL   (United States)

^bu YALE UNIVERSITY   (United States)

^bv UNIVERSITY OF TORONTO   (Canada)

^bw Fred Hutchinson Cancer Research Center   (United States)

^bx UNIVERSITY OF WASHINGTON   (United States)

^by DUKE CANCER INSTITUTE   (United States)

^bz Praxis Für Humangenetik   (Germany)

^ca VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^cb UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^cc GLASGOW ROYAL INFIRMARY   (United Kingdom)

^cd UNIVERSITY OF ULM   (Germany)

^ce MEDICAL UNIVERSITY OF WARSAW   (Poland)

^cf DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; RNA POLYMERASE II; TRANSCRIPTION FACTOR PAX8; GREEN FLUORESCENT PROTEIN; HOMEODOMAIN PROTEIN; HOXD9 PROTEIN, HUMAN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ALLELE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER RISK; COLLOID CARCINOMA; COLORECTAL CARCINOMA; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENHANCER REGION; FALSE POSITIVE RESULT; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MUCINOUS OVARIAN CARCINOMA; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS; RNA STABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; CELL NUCLEUS; CHROMOSOME 2; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR CELL LINE;

ADENOCARCINOMA, MUCINOUS; BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GREEN FLUORESCENT PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 84938292950     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3336     Document Type: Article

References (71)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Hall, J.M. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689 (1990).
3. Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108, 18032-18037 (2011).
4. Lynch, H.T. et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 56, 939-951 (1985).
5. Lynch, H.T., Conway, T. & Lynch, J. Hereditary ovarian cancer. Pedigree studies, Part II. Cancer Genet. Cytogenet. 53, 161-183 (1991).
6. Boyd, J. & Rubin, S.C. Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol. Oncol. 64, 196-206 (1997).
7. Narod, S.A. et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer 74, 2341-2346 (1994).
8. Risch, H.A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98, 1694-1706 (2006).
9. Song, H. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41, 996-1000 (2009).
10. Goode, E.L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874-879 (2010).
11. Bolton, K.L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 42, 880-884 (2010).
12. Pharoah, P.D. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet. 45, 362-370 (2013).
13. Bojesen, S.E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371-384 (2013).
14. Permuth-Wey, J. et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat. Commun. 4, 1627 (2013).
15. Couch, F.J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9, e1003212 (2013).
16. Chen, K. et al. Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. Nat. Commun. 5, 4682 (2014).
17. Kuchenbaecker, K.B. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat. Genet. 47, 164-171 (2015).
18. Vaughan, S. et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat. Rev. Cancer 11, 719-725 (2011).
19. Risch, H.A., Marrett, L.D., Jain, M. & Howe, G.R. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am. J. Epidemiol. 144, 363-372 (1996).
20. Pearce, C.L. et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol. 13, 385-394 (2012).
21. Faber, M.T. et al. Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case-control studies. Cancer Causes Control 24, 989-1004 (2013).
22. Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654-2663 (2012).
23. Köbel, M. et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5, e232 (2008).
24. Gilks, C.B. et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 39, 1239-1251 (2008).
25. Tavassoulu, F.A. & Devilee, P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs (IARC Press, 2003).
26. Seidman, J.D., Kurman, R.J. & Ronnett, B.M. Primary and metastatic mucinous adenocarcinomas in the ovaries: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am. J. Surg. Pathol. 27, 985-993 (2003).
27. Ronnett, B.M. et al. Mucinous borderline ovarian tumors: Points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum. Pathol. 35, 949-960 (2004).
28. Ronnett, B.M. et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei." Am. J. Surg. Pathol. 19, 1390-1408 (1995).
29. Lee, K.R. & Young, R.H. The distinction between primary and metastatic mucinous carcinomas of the ovary: Gross and histologic findings in 50 cases. Am. J. Surg. Pathol. 27, 281-292 (2003).
30. Yemelyanova, A.V., Vang, R., Judson, K., Wu, L.S. & Ronnett, B.M. Distinction of primary and metastatic mucinous tumors involving the ovary: Analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am. J. Surg. Pathol. 32, 128-138 (2008).
31. Hart, W.R. Mucinous tumors of the ovary: A review. Int. J. Gynecol. Pathol. 24, 4-25 (2005).
32. Cuatrecasas, M., Villanueva, A., Matias-Guiu, X. & Prat, J. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 79, 1581-1586 (1997).
33. Pieretti, M. et al. Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest. 20, 11-23 (2002).
34. Ichikawa, Y. et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54, 33-35 (1994).
35. Feeley, K.M. & Wells, M. Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87-95 (2001).
36. Heinzelmann-Schwarz, V.A. et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br. J. Cancer 94, 904-913 (2006).
37. Marquez, R.T. et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11, 6116-6126 (2005).
38. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
39. Shen, H. et al. Epigenetic analysis leads to identification of HNF1B as a subtypespecific susceptibility gene for ovarian cancer. Nat. Commun. 4, 1628 (2013).
40. Kelemen, L.E. & Kobel, M. Mucinous carcinomas of the ovary and colorectum: Different organ, same dilemma. Lancet Oncol. 12, 1071-1080 (2011).
41. Chen, J.M., Ferec, C. & Cooper, D.N. A systematic analysis of disease-associated variants in the 3 regulatory regions of human protein-coding genes II: The importance of mRNA secondary structure in assessing the functionality of 3 UTR variants. Hum. Genet. 120, 301-333 (2006).
42. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
43. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
44. Brown, C.D., Mangravite, L.M. & Engelhardt, B.E. Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet. 9, e1003649 (2013).
45. Li, H., Huang, C.J. & Choo, K.B. Expression of homeobox genes in cervical cancer. Gynecol. Oncol. 84, 216-221 (2002).
46. Tabuse, M. et al. Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol. Cancer 10, 60 (2011).
47. Laury, A.R. et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am. J. Surg. Pathol. 34, 627-635 (2010).
48. Laury, A.R. et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am. J. Surg. Pathol. 35, 816-826 (2011).
49. Cheung, H.W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 108, 12372-12377 (2011).
50. Muratovska, A., Zhou, C., He, S., Goodyer, P. & Eccles, M.R. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22, 7989-7997 (2003).
51. Di Palma, T., Lucci, V., de Cristofaro, T., Filippone, M.G. & Zannini, M. A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells. BMC Cancer 14, 292 (2014).
52. Duggal, P. et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: Data from multiple cohorts. Ann. Intern. Med. 158, 235-245 (2013).
53. Ochi, H. et al. IL-28B predicts response to chronic hepatitis C therapy-finemapping and replication study in Asian populations. J. Gen. Virol. 92, 1071-1081 (2011).
54. Key, F.M. et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon ?4 (IFNL4). PLoS Genet. 10, e1004681 (2014).
55. Urban, T.J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896 (2010).
56. Pejovic, T. Genetic changes in ovarian cancer. Ann. Med. 27, 73-78 (1995).
57. Houlston, R.S. et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat. Genet. 42, 973-977 (2010).
58. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353-361 (2013).
59. Eeles, R.A. et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45, 385-391 (2013).
60. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
61. Permuth-Wey, J. et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 71, 3896-3903 (2011).
62. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179-181 (2012).
63. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
64. Xing, G., Lin, C.Y., Wooding, S.P. & Xing, C. Blindly using Wald's test can miss rare disease-causal variants in case-control association studies. Ann. Hum. Genet. 76, 168-177 (2012).
65. Coetzee, S.G. et al. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Hum. Mol. Genet. doi:10.1093/hmg/ddv101 (24 March 2015).
66. Price, A.L. et al. Principal components analysis corrects for stratification in genomewide association studies. Nat. Genet. 38, 904-909 (2006).
67. Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633-641 (2013).
68. Li, Q. et al. Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum. Mol. Genet. 23, 5294-5302 (2014).
69. Kunzmann, R. & Holzel, F. Karyotype alterations in human ovarian carcinoma cells during long-term cultivation and nude mouse passage. Cancer Genet. Cytogenet. 28, 201-212 (1987).
70. Li, N.F. et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab. Invest. 84, 923-931 (2004).
71. Pomerantz, M.M. et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 41, 882-884 (2009).